Upon PD-1 binding to its ligands, programmed cell death ligand 1 or 2 (PD-L1/PD-L2) on tumor cells, T cell receptor (TCR) signaling and CD28 co-stimulation is inhibited, ultimately leading to effector cell inactivation [8,9]. Here, PDCD1 is linked to neoplasm.